ArticleEuropean journal of medical research2025
Predicting PIK3CA mutation in breast cancer with machine learning based multimodal image radiomics.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mammography-Based Radiomics for Prediction of Nodal Status and Disease Burden in Breast Cancer: A Temporally Validated Study.Cancers · 2026Article
- Advances in Breast Cancer Diagnostics: From Screening to Precision Medicine.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGene status may help determine molecular targeted therapy for patients with breast cancer (BC). The present study aimed to explore machine learning (ML) approaches for the early prediction of PIK3CA mutation based on mammography (MMG) and ultrasound (US) radiomics.
methodsWe analysed 186 primary BC patients (130 in the training set and 56 in the test set) who underwent PIK3CA gene testing and with pretreatment MMG and US images from January 2020 to December 2023 at our institution. PIK3CA mutation results were used as the reference standard. The MMG and US radiomics features were extracted using 3D slicer and PyRadiomics software. Three machine learning (ML) algorithms, namely, logistic regression (LR), adaptive boosting (AdaBoost), and Naive Bayes (NB) were applied to construct and validate the radiomics and combined clinicopathological-radiomics predictive models.
resultsFifty-nine (31.7%) BC patients (41 in the training set and 18 in the test set) had PIK3CA mutations. Clinicopathological (C) factors including estrogen receptor (ER) and progesterone receptor (PR) positivity were associated with PIK3CA mutation. The AUC values of the MMG-based radiomics were 0.656 (NB), 0.700 (AdaBoost), and 0.718 (LR), while those of the US-based radiomics models were 0.732 (NB), 0.754 (AdaBoost) and 0.788 (LR) in the test set. The predictive ability of clinicopathological-radiomics C + US + LR model was greater (AUC, 0.827; 95% CI 0.706, 0.942) than that of the C + MMG + LR model (AUC, 0.740; 95% CI 0.611, 0.867; p < 0.05). The hybrid C + US + MMG + LR model achieved greater efficacy (AUC, 0.899; 95% CI 0.783, 0.984) than the C + US + MMG + AdaBoost (AUC, 0.860; 95% CI 0.739, 0.974), and C + US + MMG + NB (AUC, 0.838; 95% CI 0.721, 0.952; all p < 0.05) models in the test set.
conclusionUS-based radiomics showed better predictive ability than MMG-based radiomics model. The hybrid clinicopathological and US + MMG + LR model with improved performance can assist tailored therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.